INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,078,800 | +478.6% | 220,000 | +335.6% | 0.03% | +433.3% |
| Q3 2022 | $705,000 | +94.2% | 50,503 | +126.5% | 0.01% | +100.0% |
| Q1 2022 | $363,000 | -76.3% | 22,300 | -76.3% | 0.00% | -78.6% |
| Q4 2021 | $1,534,000 | +21.2% | 94,164 | +10.4% | 0.01% | +7.7% |
| Q3 2021 | $1,266,000 | +429.7% | 85,264 | +1380.8% | 0.01% | +160.0% |
| Q3 2020 | $239,000 | -85.1% | 5,758 | -82.8% | 0.01% | -76.2% |
| Q2 2020 | $1,600,000 | +140.2% | 33,390 | +521.2% | 0.02% | +31.2% |
| Q4 2019 | $666,000 | -68.8% | 5,375 | -83.3% | 0.02% | -74.6% |
| Q3 2019 | $2,137,000 | +194.4% | 32,200 | -21.0% | 0.06% | -4.5% |
| Q3 2017 | $726,000 | -40.0% | 40,738 | +265.9% | 0.07% | -58.0% |
| Q4 2016 | $1,209,000 | – | 11,134 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |